Business · 07/08/2023
FDA Clears Daptomycin Powder for Injection for Approval of Generic Versions
The FDA has determined that Cubicin (daptomycin) powder for injection, 250mg/vial and 500mg/vial, and Cubicin RF (daptomycin) powder for injection, 500mg/vial, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for the approval of generic versions of the medication.